Calyxo, Inc.
- Industry
- Medical Devices
- Founded Year
- 2016
- Headquarters
- Pleasanton, California
- Employee Count
- 201
Key People
- Joseph Catanese - President and CEO
- Jee Shin - Founder and Chief Business Officer
- Doug Hughes - Chief Financial Officer
- Eric Steuben - Senior Vice President, Operations
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in the MedTech industry.
Calyxo's leadership includes individuals with proven track records in medical device innovation and commercialization, positioning the company favorably in the MedTech sector.
- Clinical Need
-
Aspect: Very Strong
Summary: Kidney stones are a prevalent and growing health concern, necessitating effective treatment solutions.
The prevalence of kidney stones has increased from 3.8% in the late 1970s to 11% in 2021, highlighting a substantial demand for innovative treatments.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has several existing solutions, but Calyxo's CVAC System offers unique advantages.
While there are multiple kidney stone treatment devices available, the CVAC System's all-in-one approach and superior stone clearance rates provide a competitive edge.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves manageable complexities with predictable outcomes.
The CVAC System integrates existing technologies in a novel way, leading to predictable technical challenges that can be effectively managed.
- Patent
-
Aspect: Strong
Summary: The company holds robust patents protecting its innovative technology.
Calyxo's patents cover key aspects of the CVAC System, providing a competitive advantage and potential barriers to entry for competitors.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding to support its operations and growth.
With a $50 million Series D financing round led by Avidity Partners and participation from existing investors, Calyxo is well-positioned for product development and market expansion.
- Regulatory
-
Aspect: 510k/PMA
Summary: The CVAC System has received FDA clearance, facilitating market entry.
FDA clearance for the redesigned CVAC System allows Calyxo to market its product in the U.S., a critical step for business growth.
Opportunity Rollup
- Odds of Success
- 3.5
- Peak Market Share
- 4.4
- Segment CAGR
- 5.9%
- Market Segment
- Nephrology and Urology Devices
- Market Sub Segment
- Kidney Stone Treatment Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.66 |
| 3 | 1.54 |
| 4 | 3.08 |
| 5 | 4.40 |
Key Takeaway
Calyxo's innovative CVAC System addresses a significant clinical need with a strong team and solid financial backing, positioning the company well in a growing market despite competitive challenges.